Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26347
Title: Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.
Austin Authors: Da Gama Duarte, Jessica;Woods, Katherine;Quigley, Luke T;Deceneux, Cyril;Tutuka, Candani;Witkowski, Tom ;Ostrouska, Simone;Hudson, Chris;Tsao, Simon Chang-Hao;Pasam, Anupama;Dobrovic, Alexander ;Blackburn, Jonathan M;Cebon, Jonathan S ;Behren, Andreas
Affiliation: Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa
Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa
Olivia Newton-John Cancer Research Institute
School of Cancer Medicine, La Trobe University, Bundoora, VIC 3086, Australia
Medicine (University of Melbourne)
Medical Oncology
Department of Clinical Pathology, Melbourne Medical School, University of Melbourne, Parkville, VIC 3010, Australia
Issue Date: 9-Apr-2021
Date: 2021-04-09
Publication information: Cancers 2021; 13(8): 1805
Abstract: Antibodies that block immune regulatory checkpoints (programmed cell death 1, PD-1 and cytotoxic T-lymphocyte-associated antigen 4, CTLA-4) to mobilise immunity have shown unprecedented clinical efficacy against cancer, demonstrating the importance of antigen-specific tumour recognition. Despite this, many patients still fail to benefit from these treatments and additional approaches are being sought. These include mechanisms that boost antigen-specific immunity either by vaccination or adoptive transfer of effector cells. Other than neoantigens, epigenetically regulated and shared antigens such as NY-ESO-1 are attractive targets; however, tissue expression is often heterogeneous and weak. Therefore, peptide-specific therapies combining multiple antigens rationally selected to give additive anti-cancer benefits are necessary to achieve optimal outcomes. Here, we show that Ropporin-1 (ROPN1) and 1B (ROPN1B), cancer restricted antigens, are highly expressed and immunogenic, inducing humoral immunity in patients with advanced metastatic melanoma. By multispectral immunohistochemistry, 88.5% of melanoma patients tested (n = 54/61) showed ROPN1B expression in at least 1 of 2/3 tumour cores in tissue microarrays. Antibody responses against ROPN1A and ROPN1B were detected in 71.2% of melanoma patients tested (n = 74/104), with increased reactivity seen with more advanced disease stages. Thus, ROPN1A and ROPN1B may indeed be viable targets for cancer immunotherapy, alone or in combination with other cancer antigens, and could be combined with additional therapies such as immune checkpoint blockade.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26347
DOI: 10.3390/cancers13081805
ORCID: 0000-0003-4289-5204
0000-0003-3474-3104
0000-0003-4975-7779
0000-0002-8074-045X
0000-0001-7582-3990
0000-0003-3414-112X
0000-0001-8988-9595
0000-0001-5329-280X
Journal: Cancers
PubMed URL: 33918976
ISSN: 2072-6694
Type: Journal Article
Subjects: ROPN1
ROPN1B
Ropporin-1
Ropporin-1B
melanoma
tumour antigens
Appears in Collections:Journal articles

Show full item record

Page view(s)

44
checked on Oct 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.